See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

Todd speaks about Levemir

Todd Hobbs

Todd speaks about Levemir

New Small Molecule Drugs for Type 2 - Human Trials Underway

Christoph Westphal, MD, Ph.D

New Small Molecule Drugs for Type 2 - Human Trials Underway

Multi-Talented Diabetes Educator Is a Joy to the World

Joy Pape, RN, BSN, CDE, WOCN, CFCN

Multi-Talented Diabetes Educator Is a Joy to the World

Diabetes and Actos

Page 3
Actos May Improve Heart Safety in Type 2s
Sep 1, 2005 | 
Actos, an insulin sensitizer in the glitazone class of type 2 oral diabetes medications, was found to reduce carotid artery intima-media thickness (IMT) as well as insulin resistance in a German study.
Byetta Now Available for Type 2s
Jul 1, 2005 | 
“People who are no longer successful on oral agents can now add Byetta [exenatide] instead of insulin,” says Anne Peters, MD, director of the USC Clinical Diabetes Programs.
DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

Todd speaks about Levemir

Todd Hobbs

Todd speaks about Levemir

New Small Molecule Drugs for Type 2 - Human Trials Underway

Christoph Westphal, MD, Ph.D

New Small Molecule Drugs for Type 2 - Human Trials Underway

Multi-Talented Diabetes Educator Is a Joy to the World

Joy Pape, RN, BSN, CDE, WOCN, CFCN

Multi-Talented Diabetes Educator Is a Joy to the World

Weighing the Evidence: Blood Glucose Levels Decrease with Insulin Sensitizer Despite Weight Increase
Nov 1, 2002 | 
A shift in fat distribution from visceral (the internal abdominal area) to subcutaneous (under the skin) could be the reason the insulin sensitizer Actos (pioglitazone) helps to lower blood glucose levels in people with insulin resistance.
A Research Extravaganza
Aug 1, 2002 | 
Once again, Diabetes Health has read through more than 2,500 abstracts of research presented at the American Diabetes Association's annual Scientific Sessions and selected a few of the more interesting ones to pass along to you as part of our annual "Research Extravaganza" feature.
Avandia and ACTOS Hit The Ground Running—Rezulin Competitors Show No Liver Toxicity in Clinical Trials
Sep 1, 1999 | 
Two new drugs have received approval from the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes. In clinical trials, Avandia (rosiglitazone maleate) and ACTOS (pioglitazone hydrochloride) lowered blood sugars an average of 76 mg/dl and 95 mg/dl respectively, when compared to a placebo.
« Previous Page
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.